Status:
UNKNOWN
Immune Checkpoint Inhibitors and Radiotherapy in Relapsed/Refractory Hodgkin Lymphoma
Lead Sponsor:
Ospedale Maggiore Di Trieste
Conditions:
Hodgkin Lymphoma
Immune Checkpoint Inhibitor
Eligibility:
All Genders
18+ years
Brief Summary
This is an observational retrospective study to investigate the efficacy and safety of the treatment with an immune checkpoint inhibitor (nivolumab or pembrolizumab) in combination with radiotherapy i...
Detailed Description
In patients with relapsed/refractory Hodgkin lymphoma, treatment with immune checkpoint inhibitors (ICIs), nivolumab and pembrolizumab, leads to 20-30% of complete remission (CR) rate. This means that...
Eligibility Criteria
Inclusion
- age ≥18 years
- diagnosis of classical Hodgkin lymphoma, treated with one immune checkpoint inhibitor (ICI) (nivolumab or pembrolizumab), as per label indication
- having received a concomitant radiotherapy, as per clinical need (persistence of localized disease, bulky disease, other reasons). "Concomitant" radiotherapy means a treatment received during the administration of ICI, or during the 8 weeks that precede or follow the start or the end of the treatment with ICI
Exclusion
- Having received a treatment with an ICI and radiotherapy not "concomitant", according to the abovementioned definition
- Having received any other anti-lymphoma treatments during the same period of time
- Patients who have not been evaluated by CT-PET or CT at the end of the combination therapy
Key Trial Info
Start Date :
June 24 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 30 2020
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT04419441
Start Date
June 24 2020
End Date
September 30 2020
Last Update
September 16 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
SC Ematologia Ospedale Maggiore
Trieste, Italy, 34100